Leukemiaassociated

Leukemia-associated is an adjective used in medical literature to describe features, conditions, or biomarkers that are linked to leukemia, a group of hematologic malignancies characterized by abnormal proliferation of white blood cells. It is not a disease name by itself but a descriptor applied across various clinical and research contexts.

In research and immunology, leukemia-associated antigens (LAAs) are proteins expressed by leukemic cells that can be recognized by the immune system. LAAs are studied as targets for cancer immunotherapies, including vaccines and adoptive T-cell therapies. Well-known examples include WT1, PRAME, MAGE family members, RHAMM, survivin, and NY-ESO-1, among others. Their expression can aid in diagnosis, prognosis, monitoring, and the selection of targeted treatment approaches.

In clinical practice, the descriptor also appears in reference to syndromes and complications that accompany leukemia. For example, leukemia-associated coagulopathy describes coagulopathy that can occur with certain leukemias, notably acute promyelocytic leukemia, where disseminated intravascular coagulation and bleeding risk are increased. Leukemia can also cause organ infiltration, immune dysregulation, and cytopenias, all of which may be described as leukemia-associated features. The precise meaning is context-dependent, and clinicians rely on the specific noun it modifies, such as coagulopathy, antigens, or manifestations.